Apogenix AG

NX-5948, Nurix Therapeutics’ treatment for relapsed or refractory chronic lymphocytic leukemia, and Ga68-PentixaFor, Pentixapharm’s radiodiagnostic for primary aldosteronism, are the latest investigat

Patients with glioblastoma can expect to live a median eight months after diagnosis, but two anticipated launches in 2024 and a rich development pipeline could improve that bleak clinical outlook. “Th

The first three weeks of December saw Chinese biotechs raise record amounts of new funding, with Beijing-based BeiGene, Ltd. smashing the record for an initial public offering (IPO) on Shanghai’s ST

CANbridge Life Sciences Ltd. has been front and center about its desire to accelerate the development of novel and orphan drugs in China. To this end, in the first few days of the new year, the Beiji